Cullinan Management Receives ‘Buy’ Rating as Phase 2b Study Success and Taiho Partnership Boost Prospects
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Cullinan Management (CGEM – Research Report). The associated price ...
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on ...